Goldman Sachs Injects $20M In China Biotech Firm Ascletis

Login to View

Hangzhou-based biotech firm Ascletis has received US$20 million from Goldman Sachs, bringing the company’s total fundraising to US$55 million, according to a company announcement.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Read 2 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription!

Enjoy comprehensive and exclusive data you can't find elsewhere!

More Info

Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in